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Abstract—
Background: Clinical trial registries can be used to monitor the production of trial evidence and signal when systematic reviews
become out of date. However, this use has been limited to date due to the extensive manual review required to search for and screen
relevant trial registrations. Our aim was to evaluate a new method that could partially automate the identification of trial registrations
that may be relevant for systematic review updates.
Materials and Methods: We identified 179 systematic reviews of drug interventions for type 2 diabetes, which included 537 clinical
trials that had registrations in ClinicalTrials.gov. Text from the trial registrations were used as features directly, or transformed using
Latent Dirichlet Allocation (LDA) or Principal Component Analysis (PCA). We tested a novel matrix factorisation approach that uses a
shared latent space to learn how to rank relevant trial registrations for each systematic review, comparing the performance to document
similarity to rank relevant trial registrations. The two approaches were tested on a holdout set of the newest trials from the set of type 2
diabetes systematic reviews and an unseen set of 141 clinical trial registrations from 17 updated systematic reviews published in the
Cochrane Database of Systematic Reviews. The performance was measured by the number of relevant registrations found after
examining 100 candidates (recall@100) and the median rank of relevant registrations in the ranked candidate lists.
Results: The matrix factorisation approach outperformed the document similarity approach with a median rank of 59 (of 128,392
candidate registrations in ClinicalTrials.gov) and recall@100 of 60.9% using LDA feature representation, compared to a median rank of
138 and recall@100 of 42.8% in the document similarity baseline. In the second set of systematic reviews and their updates, the
highest performing approach used document similarity and gave a median rank of 67 (recall@100 of 62.9%).
Conclusions: A shared latent space matrix factorisation method was useful for ranking trial registrations to reduce the manual
workload associated with finding relevant trials for systematic review updates. The results suggest that the approach could be used as
part of a semi-automated pipeline for monitoring potentially new evidence for inclusion in a review update.
Index Terms—Systematic reviews, clinical trial, information retrieval, matrix factorisation.
F
1 BACKGROUND
S YSTEMATIC reviews of clinical trials are at the founda-tion of evidence-based medicine and should represent
comprehensive, high quality, and up to date syntheses of
trial evidence. With the rapid growth of the scientific liter-
ature, identifying relevant evidence and keeping systematic
reviews up to date is increasingly difficult. Studies exam-
ining the timing of systematic reviews suggest that reviews
are updated on average every 5.5 years, though a substantial
proportion should be updated within 2 years [1-4]. Perform-
ing systematic reviews is time and resource intensive and
even determining when a systematic review needs updating
often requires completion of the searching and screening
steps of the systematic review process. To facilitate this
assessment, a number of tools and guidelines have been
developed that aim to identify when new relevant research
becomes available, or estimate the risk that the results of the
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systematic review may have substantially changed due to
new evidence [3-10].
These approaches rely on bibliographic databases, which
are limited due to publication and reporting biases that
affect the timing and completeness of the results [11]. About
half of all trials remain unpublished two years after trial
completion, and of those that are published, around half
have missing or changed outcomes [12,13]. As a conse-
quence, bibliographic databases may not provide a complete
and timely source of relevant trial evidence for systematic
reviews. As various policies and mandates are making
prospective trial registration standard practice, clinical trial
registries are an increasingly comprehensive and timely
source of new research evidence, and in many cases may
provide a more complete and less biased record than bib-
liographic databases [14]. However, the vast majority of
methods aiming to support the identification of relevant
studies for a systematic review operate over bibliographic
databases rather than trial registries [15] and systematic
reviews often fail to incorporate any clinical trial registries
to identify relevant trials [16]. New methods for identifying
relevant trials in clinical trial registries could help determine
when systematic reviews need to be updated and support
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2living systematic reviews and automated systematic review
updates [17-19].
Our aim was to evaluate a new method to partially
automate the identification of trials that may be relevant
for systematic review updates given the existing trials in a
systematic review. This process could serve to signal when a
systematic review becomes out of date, based on the amount
and type of new evidence that is detected.
2 RELATED WORK
A number of semi-automated methods have been proposed
to identify relevant trials for inclusion in systematic reviews
and improve the efficiency of the searching and screening
processes [15,20,21]. The methods typically use the words
or concepts included in the text of published articles to
find similarities that are then used to distinguish relevant
from irrelevant articles. Some work has also been done to
directly extract information on populations, interventions,
comparators, and outcomes [22,23], which can then be used
to match search queries. Several approaches have included
the use of active learning [24,25], while others have exam-
ined representations that use neural network based vector
space models [26]. Far less work has been performed on
identifying trials from the information stored in clinical
trial registries or on linking clinical trial registries to biblio-
graphic databases [14,27-29]. However, some methods have
shown that it is possible to identify meaningful clusters of
similar trials within registries [30-32], especially in relation
to populations [33], and ClinicalTrials.gov data has been
used in predicting black box warnings [34].
Matrix factorisation has the potential to support the
identification of relevant trials for inclusion in systematic
reviews. The approach has a long history of use in ad-
dressing problems in link prediction [35-37], for example
in building systems that recommend books, music, or new
social connections to users. This process, commonly referred
to as “the item prediction problem”, aims to predict the
presence or absence of links between the nodes of a graph
where the vertices represent users and items, and edges
that connect vertices are weighted according to preference
scores. Matrix factorisation produces a mapping between
users and items into a low-dimensional representation (la-
tent factors) to model the user-item affinity in vector space.
Past work on the use of matrix factorisation for collab-
orative filtering focused on increasing prediction accuracy
by including neighbourhood information [38]. Later, Koren
et al. [39] proposed SVD++, a matrix factorisation approach
that unified neighbourhood and latent factors. Guo et al. [40]
proposed TrustSVD, an extension of SVD++ that incorpo-
rates social trust information to help mitigate data sparsity
and the cold start problem. TrustSVD includes factorisation
of two matrices that share a same latent spaceâA˘Tˇmeaning
a matrix of user-item preference scores and another matrix
that defines trust information among users.
Our proposed matrix factorisation approach shares
structural similarity with TrustSVD but applies different
regularization methods to adapt to weighted links between
systematic reviews and trial registrations. To the best of our
knowledge, this is the first study to address the problem
of recommending trial registrations for systematic review
updates using matrix factorisation with a shared latent
space.
3 MATERIALS AND METHODS
3.1 Study data
We searched PubMed and Embase for systematic reviews
of drugs used to treat type 2 diabetes. The final search
was performed on 26 March 2017, using a search strategy
that included terms for type 2 diabetes, type 2 diabetes
interventions, and publication type information. Systematic
reviews were considered for inclusion in the experiments
if they were focused on populations with type 2 diabetes
and included at least one meta-analysis (Figure 1). Reviews
that summarised or synthesised meta-analyses from other
reviews were excluded, as were reviews that did not include
full details of a search strategy and did not include at least
one meta-analysis of a safety or efficacy outcome. Reviews
that also included other populations were included only if
they had sub-group analyses that were specific to type 2
diabetes.
After excluding systematic reviews that did not have
links to at least 4 trial registrations, we had 179 systematic
reviews with 4,447 links to 537 unique trial registrations. For
each systematic review, we ordered the registrations by trial
completion date to use older trials for training and newer
trials for testing, simulating the way new trials might be
added to existing systematic reviews. Trial registrations had
a median of 14 links (ranging from 4 to 147) to the systematic
reviews.
Fig. 1: From 2,854 unique articles identified in the search,
230 systematic reviews of type 2 diabetes were identified
and 179 were included in the experiments.
We accessed ClinicalTrials.gov on May 16, 2017 to create
a static local version of information from 128,392 completed
trials in order to produce consistent results across all exper-
iments. Information on the brief and official titles, detailed
description, inclusion criteria, and intervention names were
extracted for use in the experiments.
To test the methods in a general scenario, we additionally
identified 17 systematic reviews that were published in the
3Cochrane Database of Systematic Reviews on any topic. To
be included in the experiments, they must have either had
an update published with a new search performed before
25 April 2017, or have listed at least three ongoing studies
in ClinicalTrials.gov in the published review. We then used
the set of included trials as the training set, and the new
trials added to the update (or listed as ongoing trials) as
the test set. There were 72 unique trials in the original
reviews and 69 unique trials in the updates and lists of
ongoing relevant trials. The number of trial registrations
per systematic review was between 1 and 14 in the original
versions and between 1 and 13 in the updates.
3.2 Feature representations
Each of the trial registrations was considered as a sin-
gle document and treated as a bag of words (order was
not considered). Each word in the text was converted to
lowercase, standard stop words were excluded, the Porter
stemmer [41] was applied, and words present in fewer than
five trial registrations were excluded. Each trial registration
was represented by the set of extracted words from the text
after the pre-processing step.
We used multiple feature representations for each trial
registration. First, a binary vector representation was cre-
ated to indicate whether a word feature is present or ab-
sent in the text of a trial registration. Secondly, a word
frequency vector representation was used to capture the
number of times a word feature appears in the text of a
trial registration. Lastly, we used a term frequency-inverse
document frequency (tf-idf) vector representation, where
the entry of the vector is the tf-idf score of a word feature. In
the experiments that follow, we refer to these three feature
representations as full-dimension feature representations.
We used Principal Component Analysis (PCA) and La-
tent Dirichlet Allocation (LDA) to reduce the dimensionality
of the feature spaces. The PCA technique transforms data
into a lower-dimensional space based on several linearly
uncorrelated variables by maximising the variance. We used
the implementation of incremental PCA from scikit-learn
with its default settings, and tested it with 20, 50, 100, 200,
300, and 400 components on the tf-idf and word frequency
vector representations. The LDA method is a technique
that was first introduced to model topics across a set of
documents [42,43]. It uses co-occurrence of words to find
latent structures, or topics, in a corpus of documents and a
topic is represented by a distribution of word probabilities
for that topic. Using LDA, a trial registration is represented
by a distribution of topics, where the number of topics is set
by parameter. For LDA, we used the gensim implementation
with standard settings [44], and tested it with 20, 50, 100,
200, 300 and 400 topics. We refer the feature representations
using PCA and LDA as reduced-dimension feature repre-
sentations.
Given a systematic review, one approach to identify
relevant trial registrations is to rank all trial registrations
according to their similarity with the set of trial registrations
for trials included in the review. To determine similarity, we
used three document similarity measures: cosine similarity,
Euclidean distance, and squared Euclidean distance. These
measures were used as a baseline approach against which
the matrix factorisation approach was tested. The overall
process is illustrated in Figure2.
Fig. 2: High-level view of ranking process for trial inclusion
in systematic review updates.
3.3 Matrix factorisation with a shared latent space
Matrix factorisation decomposes a matrix into products
of matrices. In our approach, we combine two available
sources of information: the text from each trial registration
and the links between the trial registrations and the sys-
tematic reviews in which they were included. The approach
integrates both sources of information via a shared latent
space in the learning process to rank all other trial registra-
tions relative to the systematic reviews.
Given U trial registrations and V systematic reviews,
where each trial registration is represented by an J -
dimensional feature vector extracted from its text and an V -
dimensional binary vector to denote the absence or present
of a link between a trial registration and a systematic review,
we created two matrices: a matrix of trial registrations-
features, R ∈ RU×J ; and a matrix of trial registrations-
systematic reviews, T ∈ {0,1}U×V . Given K latent factors
(where K  J and K  V ), matrices R and T are then
decomposed into the following:
R ≈ PQ>, P ∈ RU×K , Q ∈ RJ×K
T ≈ PW>, P ∈ RU×K ,W ∈ RV×K
In these equations, P is a matrix of trial registration-
latent factors, Q is a matrix of trial registration feature-latent
factors and W is a matrix of systematic review-latent factors
(Figure 3).
4Fig. 3: The illustration of matrix factorisation for (a) the
matrix of trial registry entries-features; and (b) the matrix
of trial registries-systematic reviews.
Note that the matrix P is shared and used to connect
both R and T in the decomposition process. In other words,
the matrix P will describe how trial registrations are as-
sociated with systematic reviews based on the features of
trial registrations. The goal of matrix factorisation is then
to learn matrices P , Q, and W . Once the matrices are
learnt, their respective dot products approximate values in
matrices R and T ; i.e. Rˆ ≈ PQ> and Tˆ ≈ PW>. For
the unknown values in matrix T where link information
between trial registrations and systematic reviews is not
present, the respective approximated values in matrix Tˆ are
used as a measure of similarity that can then be used to rank
unknown trial registrations for each systematic review.
Because the matrix of trial registrations-features, R ∈
RU×J , is decomposed into a matrix of trial registration-
latent factor P ∈ RU×K and a matrix of trial registration
feature-latent factor Q ∈ RJ×K , the loss function that we
need to minimise is as follows [37,40]:
L =
1
2
∑
u
∑
j
(rˆuj − ruj)2 + λ
2
(
∑
u
‖pu‖2F +
∑
j
‖qj‖2F )
(1)
where || · || represents the Frobenius norm, λ is the regu-
larization parameter, ruj is the entry of matrix R in row
u and column j, and rˆuj = puq>j . pu and qj represent K-
dimensional vector of trial registration u and its feature j
respectively.
In a similar way, the matrix of (trial registrations-
systematic reviews), T ∈ {0,1}U×V , is decomposed into a
matrix of (trial registration-latent factor) P ∈ RU×K and a
matrix of (systematic review-latent factor) W ∈ RV×K , and
the loss function to minimise is as follows:
L =
1
2
∑
u
∑
v∈Tu
(tˆuv − tuv)2 + λ
2
(
∑
u
‖pu‖2F +
∑
v
‖wv‖2F )
(2)
where Tu represents a set of systematic reviews that a trial
registration belongs to, tuv is the entry of matrix T in row
u and column v, and tˆuv = puw>v . pu and wv represent
K-dimensional vector of trial registration u and systematic
review v respectively.
Because matrix is shared in Equation 1 and 2, the new
objective function to minimise is then given as follows:
L =
1
2
∑
u
∑
j
(rˆuj − ruj)2 + λt
2
∑
u
∑
v∈Tu
(tˆuv − tuv)2
+
λ
2
(
∑
u
‖pu‖2F +
∑
j
‖qj‖2F +
∑
v
‖wv‖2F ) (3)
We performed gradient descent on pu, qj and wv based
on the final loss function in Equation 3 described in the
following equations:
∂L
∂pu
=
∑
u
∑
j
eujq
>
j + λt
∑
u
∑
v∈Tu
euvw
>
v + λ
∑
u
pu
∂L
∂qj
=
∑
u
∑
j
eujpu + λ
∑
j
qj
∂L
∂wv
= λt
∑
u
∑
v
euvpu + λ
∑
v
wv (4)
where euj = rˆuj−ruj represents the feature prediction error
for trial registration u on feature j, and euv = tˆuv − tuv
represents the link prediction error for trial registration u
and systematic review v.
We used 5,000 as our maximum number of iterations for
the learning process. We calculated root-mean-square error
(RMSE) in each iteration during the learning process and re-
turned the results from the learning process when the RMSE
was the lowest. We implemented our matrix factorisation
approach in Cython. We performed the experiments with
λ=0.001, λt=0.01, and the number of latent factors was set
to 5, 10, 20, 30, 40, and 50. The source code of the proposed
matrix factorisation approach has been made available via a
repository (https://github.com/dsurian/matfac).
3.4 Experiments and outcome performance measures
For each systematic review, we split the set of links between
included trials and systematic reviews into training and test
sets with a minimum of 3 links included in the training
for each systematic review, and kept this set constant for
all experiments. Because systematic reviews had a different
number of included trials, the training set included between
3 and 89 links (a median of 9) per systematic review, and
a test set with between 1 and 58 links (a median of 5)
per systematic review. In the Cochrane systematic reviews,
the training set comprised the set of trials included in the
systematic reviews (between 1 and 14 links) and the test
set comprised the set of trials included in the update of the
systematic reviews (between 1 and 13 links).
In each experiment and for each systematic review we
produced a ranking for all 128,392 completed ClinicalTri-
als.gov registrations, and identified where the test links for
that systematic review were found in the rankings. For each
experiment, the aim was to rank the links from the test set
as high as possible within the full set of candidates. The
links corresponding to the training set were not included
5in the ranking and did not contribute to the performance
measures.
We calculated the median rank of the trials in the test set
by aggregating the ranks of all of the links in the test set
and taking the median (i.e. each trial-systematic review link
contributed one score and the median rank was calculated
from all of its scores). Using this approach, if we were to
assign a random rank to all of the trials in the test set, the
median rank would converge to approximately 64,196.
We evaluated the proportion of links in the test set
that were included in the first 100 candidates in each of
the ranked lists (recall@100), and produced a function for
the general version of the same measure (recall@N). The
recall@N function can be used to determine the number of
candidates that need to be examined per systematic review
to identify a given proportion of relevant trial registrations.
We also included the work saved over sampling (WSS) [20]
which shows the percent reduction in screening process to
retrieve the relevant trials. We measured WSS at recall 95%
(WSS@95%) by calculating the proportion of registrations
that did not need to be screened after screening the ranked
candidate registrations and identifying at least 95% of the
registrations in the test set.
To evaluate the matrix factorisation and document sim-
ilarity approaches against an appropriate baseline, we un-
dertook a manual search of ClinicalTrials.gov using the
Advanced Search function, which ranks trials based on a
relevance score. One investigator (AD) replicated the search
strategies of the reviews in the format of population, in-
tervention, and outcome (as required), and the returned
search results were used as a ranked set. These results were
evaluated using the same outcome measures.
4 RESULTS
We identified 40,049 unique words in the vocabulary ex-
tracted from the processed text of trial registrations. For
the binary and word frequency vector representations, the
number of features that were shared between training and
test sets was 2,367, comprising 5.9% of the 40,049 words
(Figure 4).
Fig. 4: The distribution of the frequency with which each
word feature was found: (a) at least once in any trial
registration; (b) at least once in the 537 type 2 diabetes trial
registrations; and (c) shared across the training and test sets
for each of the 179 systematic reviews.
For the document similarity methods, the full set of word
features with tf-idf weights consistently produced higher
levels of performance (Table 1). In the best performing
methods, half of the correct links could be identified by
checking 138 candidates (i.e., median rank of 138), and
42.8% of correct links could be identified by checking 100
candidates. Compared to the manual search, the results
from the document similarity method were 9.2% lower for
the median rank and 33.3% higher for recall@100.
The best performing matrix factorisation approach pro-
duced a recall@100 of 60.9% (and a median rank of 59),
which was achieved with the LDA feature representation
using 200 topics, and 50 latent factors. The median rank
of the best-performing matrix factorisation approach was
57.2% lower and the recall@100 was 42.3% higher than
the best performing document similarity approach, and
both methods gave a similar WSS@95%. Compared to the
manual search, the results from the matrix factorisation were
61.2% lower for the median rank and 89.7% higher for the
recall@100. The performance of matrix factorisation using
the full-dimension feature representations was consistently
lower than the performance of document similarity.
Using the matrix factorisation approach, a user would
need to examine the top 400 candidates to find 90% of
the test set, and after examining the top 700 candidates,
approximately 95% of the test set would have been found
(Figure 5).
4.1 Tests in a general scenario
The document similarity baseline gave the best perfor-
mance compared to the matrix factorisation approach in
the general scenario, which had fewer training examples.
The best-performing document similarity method produced
a median rank of 67 (recall@100: 62.9%) using all word
features and tf-idf weights and cosine similarity, while the
best-performing matrix factorisation approach produced a
median rank of 5,124 (recall@100: 1.4%) using LDA with 20
topics and 30 latent factors.
The performance of the matrix factorisation method was
lower in the general scenario than in the type 2 diabetes
examples, and lower than the document similarity methods.
To investigate possible reasons, we looked at how the results
varied with the number of training examples in the type 2
diabetes systematic reviews (Figure 6). The results indicate
that the document similarity method degrades as the num-
ber of examples decreases, while the matrix factorisation
tends to improve or maintain its performance as the number
of training examples increases (see Discussion and Figure 7).
5 DISCUSSION
Our results indicate that a shared latent space matrix fac-
torisation method can support the identification of trial
registrations that are relevant to a systematic review. Both
the matrix factorisation and document similarity methods
could be used together as part of a process to signal when a
systematic review is likely to be out of date.
5.1 Comparisons with existing research
This is the first study to evaluate matrix factorisation for
the purpose of finding new relevant trials from ClinicalTri-
als.gov for systematic review updates. In terms of manual
6TABLE 1
The results from the manual search compared to the highest performing document similarity methods and matrix
factorisation.
WSS@95% Median Rank Recall@100
Manual Search 97.0% 152 32.1%
Document Similarity
Full tf-idf weights
Euclidean distance 99.5% 139 42.6%
Squared Euclidean distance 99.5% 138 42.8%
Cosine similarity 99.5% 154 41.7%
PCA (400 components), tf-idf weights
Euclidean distance 95.5% 329.5 29.4%
Squared Euclidean distance 95.4% 341 27.4%
Cosine similarity 99.1% 195 37.0%
LDA (400 topics)
Euclidean distance 94.0% 363 23.4%
Squared Euclidean distance 93.5% 409.5 22.2%
Cosine similarity 98.0% 433 20.4%
Matrix Factorisation
PCA (300 components), tf-idf weights
5 latent factors 99.4% 76 57.6%
10 latent factors 99.3% 75 57.6%
20 latent factors 99.4% 75 57.7%
30 latent factors 99.4% 76 58.0%
40 latent factors 99.3% 74 58.1%
50 latent factors 99.4% 74 58.6%
LDA (400 topics)
5 latent factors 96.2% 78 57.1%
10 latent factors 99.0% 75.5 57.6%
20 latent factors 99.2% 77 57.4%
30 latent factors 99.2% 74 57.9%
40 latent factors 99.2% 59 60.7%
50 latent factors 99.2% 59 60.9%
screening requirements, our findings show that the per-
formance of our methods compares favourably to similar
methods that operate over bibliographic databases. While
the results of studies testing semi-automated screening of
published articles for inclusion in systematic reviews are not
directly comparable, standard tools in this area use active
learning to avoid screening 80% of articles to reach 95%
recall [20,25,26]. In our experiments, we were able to reach
95% recall after screening approximately 700 candidates
(avoiding 99.5% of the candidate registrations).
A recent study using citation links trained on 23 system-
atic reviews found that to reach 75% recall, the precision
dropped to 3.6% [45], retrieving 300 correct citations after
screening 8,298 articles. For our approach trained on 179
systematic reviews, 75% recall was reached after screening
fewer than 200 trial registrations.
In another recent example, investigators used gener-
alized linear models and gradient boosting machines on
3 systematic reviews, and needed to screen between 192
and 2,112 articles to reach 96% recall [46]. The approach
is similar to ours in that it requires knowing which studies
were included in existing systematic reviews. However, the
approach appears to have used between 6,502 and 41,066
negative training examples and between 55 and 356 positive
training examples. By comparison, our approach demon-
strated that investigators could screen a similar number
of trial registrations to reach the same level of recall, but
using fewer positive training examples with no negative
training examples. This was possible because the matrix
factorisation approach we proposed takes advantage of the
latent structure of the set of other training examples and is
therefore expected to improve with time as more training
examples become available.
5.2 Implications and recommendations
As policies and practice around the prospective registration
and structured results reporting of clinical trials continue
to expand, use of trial registries in the production of sys-
tematic reviews will likely increase. An important benefit
will include earlier identification of when the evidence
summarised in a systematic review has become out of date.
Tools that automate the identification of relevant trials or
7Fig. 5: Recall@N for various number of candidates that were needed to be checked before the trial registrations included in
the type 2 diabetes systematic reviews were found among the set of 128,392 trial registrations. The horizontal dashed-lines
mark the positions where recall 90% and 95% were achieved.
Fig. 6: Changes in the recall@100 relative to the number of
training examples for (a) the highest-performing matrix fac-
torisation method; and (b) the highest performing document
similarity method when applied to the 179 type 2 diabetes
reviews. Each systematic review contributes to the size of
the black dots, and the moving average (range of 7) and its
exact 95% confidence interval are given in red as a guide.
dramatically reduce the human workload required in trial
selection, could be applied to provide rapid estimates of
how much of the available evidence is covered in a pub-
lished systematic review, thus signalling the need for an
update. If an update cannot be produced in a specified time,
the systematic review could be flagged as potentially out of
date with reference to the new research, in order to inform
clinicians and consumers using systematic reviews in their
care decisions.
Our results suggest that the matrix factorisation ap-
proach works best when there are more trials for training
from similar systematic reviews. While the document simi-
larity approach only uses included trials from one system-
atic review to find close examples of other trial registrations,
the matrix factorisation method uses information from other
nearby systematic reviews to learn how to rank registra-
tions. Figure 7 is a t-SNE visualisation [47] of the 128,392
completed trial registrations, illustrating the differences be-
tween the 537 trials included in the 179 type 2 diabetes
systematic reviews (orange) and the 141 trials included in
the 17 Cochrane systematic reviews (blue). In the figure, the
position is determined by mapping the feature space into
two dimensions such that similar trials are located close
together. The matrix factorisation is better able to learn
the features that reproduce the known links available in
the orange region of this space, and struggles to learn the
important features for the Cochrane reviews because the
known links are more sparsely distributed across the 128,392
completed trial registrations from ClinicalTrials.gov.
The results of the experiments suggest that the document
similarity and matrix factorisation approaches can replace
the need to undertake a search of trial registrations as well
as improve the efficiency of screening for relevant trials.
This suggests that the two could be used as complementary
solutions as part of a pipeline of methods for automatically
identifying trials that may be relevant to the update of a
systematic review, or used to support updates of living
systematic reviews [17].
5.3 Limitations
The study has several limitations. First, the set of systematic
reviews used in the training and validation of the meth-
ods are related to drug interventions in type 2 diabetes–
an area with a substantial number of new drugs and a
large volume of new trials. This means that the results
may not generalise to clinical application domains with
fewer trials available [48], or where trial descriptions are
more heterogeneous. Second, our results may underestimate
the performance of both the baseline document similarity
approach and the matrix factorisation approach because we
8Fig. 7: The t-SNE visualisation of the trial registration space constructed from the PCA feature representation. The 537
unique trial registrations included in the type 2 diabetes reviews (orange), and the 141 unique trial registrations in the
Cochrane reviews (blue) are highlighted among the set of 128,392 trial registrations (grey).
only used known links to test the performance, and other
highly–ranked candidates–especially those completed since
the systematic reviews were published–may also have been
relevant but not included in the systematic review.
6 CONCLUSION
The use of clinical trial registries to monitor which and when
systematic reviews require updating has been limited by
the extensive manual processes required to identify relevant
trial registrations. To date, semi-automated article screening
methods used in bibliographic databases have not been
extended to trial registries. We found that a matrix factori-
sation method can be used to rank trial registrations such
that 75% of relevant trial registrations will appear within
the top 200 candidates. The matrix factorisation approach
for identifying trials relevant to a systematic review update
is likely to be most useful in practice if implemented in a
pipeline or in combination with other methods designed for
scenarios where no or few relevant trial registrations are
known.
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7 APPENDIX
The search strategy for identifying systematic reviews of
type 2 diabetes for PubMed (and translated to equivalent
terms for Embase):
((type 2[Title/Abstract] OR type II[Title/Abstract] OR
adult[Title/Abstract] OR slow[Title/Abstract]) AND (dia-
bete*[Title/Abstract] OR diabetic*[Title/Abstract])) AND ("meta
analysis"[Publication Type] OR "review"[Publication Type] OR
systematic review[Title/Abstract] OR meta analysis[Title/Abstract])
AND (metformin[Title/Abstract] OR glucophage[Title/Abstract]
OR dipeptidyl-peptidase iv inhibitors[Title/Abstract] OR
*gliptin[Title/Abstract] OR Januvia[Title/Abstract] OR
glucagon-like peptide[Title/Abstract] OR Galvus[Title/Abstract]
OR exenatide[Title/Abstract] OR Trajenta[Title/Abstract]
OR Byetta[Title/Abstract] OR Onglyza[Title/Abstract] OR
Bydureon[Title/Abstract] OR liraglutide[Title/Abstract] OR
Victoza[Title/Abstract] OR lixisenatide[Title/Abstract] OR
Lyxumia[Title/Abstract] OR thiazolidinedione*[Title/Abstract]
OR glitazone*[Title/Abstract] OR *glitazone[Title/Abstract] OR
Avandia[Title/Abstract) OR sulfonylurea*[Title/Abstract] OR
sulphonylurea*[Title/Abstract] OR tolbutamide[Title/Abstract]
OR glibenclamide[Title/Abstract] OR glipizide[Title/Abstract]
OR Minidiab[Title/Abstract] OR glimepiride[Title/Abstract]
OR Amaryl[Title/Abstract] OR gliclazide[Title/Abstract] OR
Diamicron[Title/Abstract])
